Document:

<PAGE>   1
                                                                   Exhibit 10.32

DUPLICATE Original No. ______ of ______

February 28, 2000

Mr. Philippe P. LeGoff
c/o Mrs. Mathilde LeGoff
111 Avenue Briand
35000 Rennes
FRANCE

         RE:      CONSULTING AGREEMENT BETWEEN PHILIPPE P. LEGOFF AND
                  BOSTON SCIENTIFIC CORPORATION

This letter constitutes a Consulting Agreement ("Agreement") between you,
Philippe P. LeGoff ("Consultant"), and Boston Scientific Corporation and its
affiliated and associated companies (collectively "Boston Scientific").

1.       FIELD OF CONSULTATION: To identify new business opportunities in the
         European Union and Eastern Europe (comprising Poland, Czech Republic,
         Croatia, Slovakia, Slovenia, and Hungary) which may be of interest to
         Boston Scientific and to advise Boston Scientific on emerging
         technologies and modalities applicable or potentially applicable to
         existing Boston Scientific business areas in the European Union and
         Eastern Europe.

2.       CONTRACT LIAISON: The performance of Consulting Services (defined
         below) under this Agreement will be coordinated through Robert G.
         MacLean ("Mr. MacLean"), the Boston Scientific executive who has been
         designated as the Contract Liaison for this Agreement (the "Contract
         Liaison"). The Contract Liaison will direct the activities of
         Consultant and from time to time specify Consultant's assignments. If
         BSC designates a new Contract Liaison to replace Mr. MacLean, it will
         provide notice to Consultant. All reports, documents, and
         communications relating to the provision of the Consulting Services
         shall be transmitted to Boston Scientific through the Contract Liaison,
         or to persons designated by the Contract Liaison. Boston Scientific may
         designate a new Contract Liaison by written notice to Consultant.
         Robert G. MacLean can be reached by calling (508) 650-8481 (unless or
         until this number changes).

3.       CONSULTING SERVICES: The Consultant is engaged to perform Consulting
         Services in the Field of Consultation as follows: (a) to assist in the
         identification, development and conduct of new and existing BSC
         business in the European Union and Eastern Europe, including, in
         particular, the identification of new business development
         opportunities in fields of current or potential interest to BSC; (b) to
         analyze and give advice to BSC in areas of current BSC

                                       1
<PAGE>   2

         business focus, with particular emphasis on the fields of endovascular
         aneurysmal repair, peripheral angioplasty, and stenting, endourological
         and gastrointestinal endoscopic procedures; and, (c) to perform other
         related tasks (the "Consulting Services") in consultation with and
         under the general direction of the Contract Liaison. BSC acknowledges
         that the Consulting Services will not be on a full-time basis and shall
         not exceed 800 hours per year, excluding travel time. Consultant will
         not be required to travel outside Europe, except for a maximum of four
         meetings per year.

4.       TERM: The initial term of this Agreement shall be for a two-year period
         commencing March 1, 2000 and ending February 28, 2002 ("Term"). The
         Term may be extended by mutual written agreement of the parties for
         additional six (6) month periods, notice of the request for any such
         extension to be given by each party to the other no later than 30 days
         prior to the expiration of the applicable term.

5.       PAYMENT:

         (a)   Boston Scientific will pay Consultant a retainer of Ninety-five
               Thousand Dollars and no cents ($95,000.00) per quarter for
               services performed by Consultant and related to Consulting
               Services. Payment for services shall be made by Boston Scientific
               within the first thirty (30) days of the commencement of each
               quarter. The first quarter will cover the period from March 1,
               2000 to May 31, 2000 and payment will be due on or before April
               15, 2000.

         (b)   Boston Scientific will reimburse Consultant for reasonable
               expenses incurred while performing the Consulting Services.
               Generally, all reimbursement requests should be submitted for
               prior approval. Major expenses, including travel expenses, must
               be approved by the Contract Liaison in advance. Invoices and
               receipts must be submitted for all expenses whenever possible.
               Payment for expense reimbursement shall be made by Boston
               Scientific within thirty (30) days after receipt of Consultant's
               reimbursement request.

6.       PERFORMANCE AND SUBSTANTIATION OF CONSULTING SERVICES: Consultant shall
         perform the Consulting Services requested by the Boston Scientific
         Contract Liaison during the Term of this Agreement. Consultant shall
         document and record all time spent in the performance of the Consulting
         Services to the reasonable satisfaction of the Boston Scientific
         Contract Liaison. This documentation shall be delivered to the Boston
         Scientific Contract Liaison in person or by fax on or before the first
         business day of each calendar quarter, such documentation to contain
         information for the prior quarter. The first such documentation shall
         be due on or before June 30, 2000.

                                       2
<PAGE>   3

7.       TERMINATION OF CONSULTING SERVICES: This Agreement will become
         effective when signed by both parties and shall continue for the Term
         specified in Section 4, above. Should Consultant breach any of his
         obligations under Paragraphs 8, 10, 11, 13, 14 and 15, below, Boston
         Scientific may terminate this Agreement upon written notice to
         Consultant if any such breach is not remedied, so long as Boston
         Scientific shall have first given Consultant a thirty (30) day
         opportunity to cure any such breach. In the event of such termination,
         Boston Scientific will, as its sole and exclusive obligation, pay
         Consultant at the rate specified in Paragraph 5, above, for Services
         rendered up to Consultant's receipt of termination notice. Upon
         termination of this Agreement, Consultant shall promptly deliver to
         Boston Scientific all Boston Scientific Property, as defined in Section
         9 below, including work in progress, which was furnished by Boston
         Scientific to Consultant. Boston Scientific may withhold final payment
         until receipt of all such Boston Scientific Property. Consultant's
         obligations under Sections 8, 10, 11, 12, 13, 14 and 15 hereof shall
         survive expiration or any termination of this Agreement. Consultant may
         terminate this Agreement at any time upon thirty (30) days prior
         written notice to BSC.

8.       CONFIDENTIAL INFORMATION:

         (a)   "Boston Scientific Confidential Information" shall mean all
               information disclosed by Boston Scientific to Consultant,
               including without limitation, information relating to the Field
               of Consultation of this Agreement, and all other information
               regarding Boston Scientific's past, present, or future research,
               technology, know-how, ideas, concepts, designs, products,
               prototypes, processes, machines, manufacture, compositions of
               matter, business plans and operations, technical information,
               drawings, specifications, and the like, and any knowledge or
               information developed by Consultant as a result of work in
               connection with this Agreement, except information which:

               (i)   is at the time of disclosure, or thereafter becomes, a part
                     of the public domain through no act or omission by
                     Consultant;

               (ii)  is lawfully in the possession of Consultant prior to
                     disclosure by Boston Scientific, as shown by Consultant's
                     written records; or

               (iii) is lawfully disclosed to Consultant by a third party which
                     did not acquire the same under an obligation of
                     confidentiality from or through Boston Scientific, as shown
                     by Consultant's written records.

         (b)   Consultant will not, without the prior written consent of Boston
               Scientific, disclose any Boston Scientific Confidential
               Information to anyone for any reason at any time or use any
               Boston Scientific Confidential Information for any purpose,
               except as requested by Boston Scientific.

                                       3
<PAGE>   4

         (c)   Consultant will not disclose to Boston Scientific any
               confidential or proprietary information belonging to any third
               party without the written consent of such party, or represent as
               being unrestricted any designs, plans, models, samples, or other
               writings or products that Consultant knows are covered by valid
               patent, copyright, or other forms of intellectual property
               protection.

9.       BOSTON SCIENTIFIC PROPERTY: To the extent that it is provided, the
         parties agree that all tangible property provided to Consultant in
         connection with this Agreement, including without limitation all
         samples, reports, communications, drawings, notes, analyses and
         materials received from Boston Scientific or produced in connection
         with this Agreement (collectively, "Boston Scientific Property"), shall
         be and remain the exclusive property of Boston Scientific. Consultant
         agrees to keep and maintain in Consultant's custody and control any
         Boston Scientific Property that Consultant receives or develops during
         the term of this Agreement, and agrees to return or surrender to Boston
         Scientific all Boston Scientific Property upon termination of this
         Agreement or otherwise upon request by Boston Scientific.

10.      DEVELOPMENT RIGHTS: Consultant shall, during the term of this Agreement
         and for a period of one (1) year thereafter, promptly report and
         disclose to Boston Scientific all improvements to Boston Scientific
         products tested and evaluated by Consultant and all ideas and concepts
         heard, developed or conceived, either alone or with others, including
         any ideas and concepts which result in new products or significant
         enhancements to existing products, while performing the Consulting
         Services ("Developments"). Developments shall be the sole and exclusive
         property of Boston Scientific and are hereby assigned to Boston
         Scientific without any additional payments to Consultant by Boston
         Scientific. It is understood that Boston Scientific shall have the
         right but not the obligation to initiate, prosecute, maintain and
         defend any and all patentable ideas and concepts with respect to
         Developments. Consultant shall provide reasonable assistance to Boston
         Scientific with respect to any such patents and patent applications,
         and shall execute all appropriate documents and assignments with
         respect to any such patents and patent applications. Consultant agrees
         not to assert any rights in law or in equity in the Developments.

11.      PUBLISHING: During the term of this Agreement and for a period of one
         (1) year thereafter, Consultant shall submit to Boston Scientific any
         paper Consultant intends to publish relating to the Field of
         Consultation of this Agreement, and shall not submit any such paper to
         a publisher or other party prior to the expiration of forty-five (45)
         days from the date an outline of the paper is submitted to Boston
         Scientific. If Boston Scientific determines in good faith during such
         period that publication or presentation of such paper would be
         detrimental to its intellectual property interests, Consultant shall
         work in good faith with Boston Scientific to retract or modify the
         paper to remove all language which is detrimental to Boston

                                       4
<PAGE>   5

         Scientific's intellectual property interests, or, in the alternative
         and at Boston Scientific's election, shall refrain from submitting such
         paper to a publisher or other party for an additional 120 days to
         permit Boston Scientific to file patent applications or take other
         steps to protect its intellectual property interests.

         During the term of this Agreement and for a period of one (1) year
         thereafter, Consultant shall also submit to Boston Scientific for
         review, on a confidential basis, any patent applications relating to
         the Field of Consultation naming Consultant as an inventor, either
         alone or with others, which Consultant or any third party intends to
         file with any U.S. or international patent offices in advance of the
         filing of any such application. Boston Scientific shall have thirty
         (30) days in which to review such applications. If Boston Scientific
         makes a good faith determination, within such period, that the filing
         of such an application would be contrary to its intellectual property
         rights set forth herein, Consultant shall amend, or cause to be
         amended, such proposed patent application to remove any language that
         is determined by Boston Scientific to be contrary to its intellectual
         property rights hereunder.

12.      INDEMNIFICATION: Consultant agrees to defend, indemnify and hold Boston
         Scientific harmless from any and all suits, claims, actions, damages or
         losses whatsoever (including reasonable attorney's fees):

         (a)   arising out of any claim that the use of the Developments by
               Boston Scientific infringes any patent or copyright or otherwise
               violates the rights of any third party; or resulting in any way
               from any act or omission of Consultant in his performance of the
               Consulting Services or his presence at a Boston Scientific
               facility.

         (b)   Consultant agrees to indemnify and hold harmless Boston
               Scientific to the extent of any obligations imposed by law on
               Boston Scientific to pay any withholding taxes, social security,
               unemployment or disability insurance, or similar items in
               connection with any payment made to Consultant by Boston
               Scientific for Consultant's services provided hereunder.

13.      NON-SOLICITATION OF BOSTON SCIENTIFIC EMPLOYEES: Consultant agrees that
         during the term of this Agreement and for a period of one (1) year
         after its termination, Consultant will not attempt to or actually
         solicit for hire any individual who was an employee of Boston
         Scientific within the twelve (12) month period immediately preceding
         the termination date of this Agreement, assist in the hiring away of
         any such employee by another person, or encourage any such employee to
         terminate his or her employment with Boston Scientific, whether
         directly or indirectly, unless the President of Boston Scientific or
         his designee shall have given prior written approval.

                                       5
<PAGE>   6

14.      CONSULTANT'S WARRANTIES: Consultant represents and warrants:

         (a)   that Consultant has the unrestricted right to disclose any
               information it submits to Boston Scientific, free of all claims
               of third parties,

         (b)   that such disclosures do not breach or conflict with any
               confidentiality provisions of any agreement to which Consultant
               is a party, and

         (c)   that the services covered by this Agreement are not in violation
               of any other agreement with other parties or of any restrictions
               of any kind.

15.      ABSENCE OF CONFLICTS: Consultant agrees and warrants that Consultant
         will not, during the term of this Agreement and for a period of one (1)
         year thereafter, work with any competitor on the development of any
         products which would be directly competitive with any existing or
         proposed Boston Scientific products of which Consultant is reasonably
         aware, or provide similar Consultantcy or consulting services relating
         to the Field of Consultation. Consultant further agrees to disclose to
         Boston Scientific, during the term of this Agreement, any services
         Consultant is providing to, or any arrangements Consultant has with,
         any competitor of Boston Scientific so that Boston Scientific can
         evaluate potential areas of conflict. For the purposes of this
         Paragraph, a "competitor" of Boston Scientific means any party in
         actual competition or intending or preparing to be in competition with
         Boston Scientific's products or business. Notwithstanding the
         foregoing, BSC acknowledges that Consultant will be establishing a
         Consulting Business that will not compete with BSC and that the
         establishment of that business is not a violation of this Agreement.

16.      PRIMACY OF AGREEMENT: This Agreement supercedes and cancels all
         previous agreements and arrangements between Consultant and Boston
         Scientific relating to the Consultant's provision of Consulting
         Services. This Agreement may be changed only by a writing signed by
         both parties.

17.      MISCELLANEOUS: This Agreement is made pursuant to the laws of the
         Commonwealth of Massachusetts and questions as to its validity and
         effect shall be governed thereby. Further, the Agreement is not
         assignable by Consultant, and shall inure to the benefit of Boston
         Scientific and its successors and assigns except that Consultant may
         assign this Agreement to any Consulting Business he creates and
         controls so long as Consultant continues personally to perform the
         Consulting Services. Consultant is an independent contractor; is
         responsible for paying all foreign, federal, state and local taxes,
         including but not limited to income, Social Security and unemployment
         taxes; and has no right to sign the name of or bind Boston Scientific
         in any manner. No failure of either party to enforce any right under
         this Agreement shall be deemed a waiver thereof.

                                       6
<PAGE>   7

18.      NOTICE: Any notice or communication required or permitted to be given
         by either party under the terms of this Agreement shall be deemed
         sufficiently given if mailed by registered mail or by a nationally
         recognized courier who guarantees overnight delivery and addressed as
         follows:

         TO BOSTON SCIENTIFIC                        TO CONSULTANT

         Robert G. MacLean                           Philippe P. LeGoff
         Senior Vice President                       c/o Mathilde LeGoff
         Human Resources                             111 Avenue Briand
         Boston Scientific Corporation               35000 Rennes, FRANCE
         One Boston Scientific Place
         Natick, MA  01760-1537

         WITH A COPY TO:

         General Counsel                             Russell F. Conn, Esq.
         Boston Scientific Corporation               Conn, Kavanaugh, Rosenthal,
         One Boston Scientific Place                    Peisch & Ford, L.L.P.
         Natick, MA  01760-1537                      Ten Post Office Square
                                                     Boston, MA  02109
                                                     (617) 482-8299
                                                     - and -
                                                     Mathys Schmid & Partners
                                                     Attn:  Dr. Peter Mathys
                                                     Dufourstrasse 5
                                                     Basel, Switzerland

         If the foregoing accurately represents our agreement, please sign at
         the appropriate place and return one copy of this Agreement to me.

BOSTON SCIENTIFIC CORPORATION

Name: Robert G. MacLean                  Title: Senior Vice President,
                                                Human Resources

Name:                                    Date:
      ------------------------                  --------------------------
         (Signature)

                                       7
<PAGE>   8

AGREED TO, ACCEPTED AND ACKNOWLEDGED:

Name: Philippe P. LeGoff

Name:                                    Date:
      ------------------------                  --------------------------
         (Signature)

                                       8<PAGE>   1

                                                                   Exhibit 10.24

                          HOUSTON STREET EXCHANGE, INC.

                            1999 STOCK INCENTIVE PLAN

1.   PURPOSE

The purpose of this 1999 Stock Incentive Plan (the "Plan") of Houston Street
Exchange, Inc., a Delaware corporation (the "Company"), is to advance the
interests of the Company's stockholders by enhancing the Company's ability to
attract, retain and motivate persons who make (or are expected to make)
important contributions to the Company by providing such persons with equity
ownership opportunities and performance-based incentives and thereby better
aligning the interests of such persons with those of the Company's stockholders.
Except where the context otherwise requires, the term "Company" shall include
any of the Company's present or future subsidiary corporations as defined in
Section 424(f) of the Internal Revenue Code of 1986, as amended, and any
regulations promulgated thereunder (the "Code").

2.   ELIGIBILITY

All of the Company's employees, officers, directors, consultants and advisors
(and any individuals who have accepted an offer for employment) are eligible to
be granted options, restricted stock awards or other stock-based awards (each,
an "Award") under the Plan. Each person who has been granted an Award under the
Plan shall be deemed a "Participant".

3.   ADMINISTRATION, DELEGATION

     (a)  ADMINISTRATION BY BOARD OF DIRECTORS. The Plan will be administered by
the Board of Directors of the Company (the "Board"). The Board shall have
authority to grant Awards and to adopt, amend and repeal such administrative
rules, guidelines and practices relating to the Plan as it shall deem advisable.
The Board may correct any defect, supply any omission or reconcile any
inconsistency in the Plan or any Award in the manner and to the extent it shall
deem expedient to carry the Plan into effect and it shall be the sole and final
judge of such expediency. All decisions by the Board shall be made in the
Board's sole discretion and shall be final and binding on all persons having or
claiming any interest in the Plan or in any Award. No director or person acting
pursuant to the authority delegated by the Board shall be liable for any action
or determination relating to or under the Plan made in good faith.

     (b)  DELEGATION TO EXECUTIVE OFFICERS. To the extent permitted by
applicable law, the Board may delegate to one or more executive officers of the
Company the power to make Awards and exercise such other powers under the Plan
as the Board may determine, provided that the Board shall fix the maximum number
of shares subject to Awards and the maximum number of shares for any one
Participant to be made by such executive officers.

     (c)  APPOINTMENT OF COMMITTEES. To the extent permitted by applicable law,
the Board may delegate any or all of its powers under the Plan to one or more
committees or subcommittees of the Board (a "Committee"). All references in the
Plan to the "Board" shall mean the Board or a Committee of the Board or the
executive officer referred to in Section 3(b)

<PAGE>   2

to the extent that the Board's powers or authority under the Plan have been
delegated to such Committee or executive officer.

4.   STOCK AVAILABLE FOR AWARDS

Subject to adjustment under Section 8, Awards may be made under the Plan for up
to 2,000,000 shares of common stock, $0.01 par value per share, of the Company
(the "Common Stock"). If any Award expires or is terminated, surrendered or
canceled without having been fully exercised or is forfeited in whole or in part
or results in any Common Stock not being issued, the unused Common Stock covered
by such Award shall again be available for the grant of Awards under the Plan,
subject, however, in the case of Incentive Stock Options (as hereinafter
defined), to any limitation required under the Code. Shares issued under the
Plan may consist in whole or in part of authorized but unissued shares or
treasury shares.

5.   STOCK OPTIONS

     (a)  GENERAL. The Board may grant options to purchase Common Stock (each,
an "Option") and determine the number of shares of Common Stock to be covered by
each Option, the exercise price of each Option and the conditions and
limitations applicable to the exercise of each Option, including conditions
relating to applicable federal or state securities laws, as it considers
necessary or advisable. An Option which is not intended to be an Incentive Stock
Option (as hereinafter defined) shall be designated a "Nonstatutory Stock
Option".

     (b)  INCENTIVE STOCK OPTIONS. An Option that the Board intends to be an
"incentive stock option" as defined in Section 422 of the Code (an "Incentive
Stock Option") shall only be granted to employees of the Company and shall be
subject to and shall be construed consistently with the requirements of Section
422 of the Code. The Company shall have no liability to a Participant, or any
other party, if an Option (or any part thereof) which is intended to be an
Incentive Stock Option is not an Incentive Stock Option.

     (c)  EXERCISE PRICE. The Board shall establish the exercise price at the
time each Option is granted and specify it in the applicable option agreement.

     (d)  DURATION OF OPTIONS. Each Option shall be exercisable at such times
and subject to such terms and conditions as the Board may specify in the
applicable option agreement.

     (e)  EXERCISE OF OPTION. Options may be exercised by delivery to the
Company of a written notice of exercise signed by the proper person or by any
other form of notice (including electronic notice) approved by the Board
together with payment in full as specified in Section 5(f) for the number of
shares for which the Option is exercised.

     (f)  PAYMENT UPON EXERCISE. Common Stock purchased upon the exercise of an
Option granted under the Plan shall be paid for as follows:

          (1)  in cash or by check, payable to the order of the Company;

          (2)  except as the Board may, in its sole discretion, otherwise
provide in an option agreement, by (i) delivery of an irrevocable and
unconditional undertaking by a

                                      -2-
<PAGE>   3

creditworthy broker to deliver promptly to the Company sufficient funds to pay
the exercise price or (ii) delivery by the Participant to the Company of a copy
of irrevocable and unconditional instructions to a creditworthy broker to
deliver promptly to the Company cash or a check sufficient to pay the exercise
price;

          (3)  when the Common Stock is registered under the Exchange Act, by
delivery of shares of Common Stock owned by the Participant valued at their fair
market value as determined by (or in a manner approved by) the Board in good
faith ("Fair Market Value"), provided (i) such method of payment is then
permitted under applicable law and (ii) such Common Stock was owned by the
Participant at least six months prior to such delivery;

          (4)  to the extent permitted by the Board, in its sole discretion by
(i) delivery of a promissory note of the Participant to the Company on terms
determined by the Board (including whether the Participant must pay cash in an
amount equal to the par value of any Common Stock issued) or (ii) payment of
such other lawful consideration as the Board may determine; or

          (5)  by any combination of the above permitted forms of payment.

6.   RESTRICTED STOCK

     (a)  GRANTS. The Board may grant Awards entitling recipients to acquire
shares of Common Stock, subject to the right of the Company to repurchase all or
part of such shares at their issue price or other stated or formula price (or to
require forfeiture of such shares if issued at no cost) from the recipient in
the event that conditions specified by the Board in the applicable Award are not
satisfied prior to the end of the applicable restriction period or periods
established by the Board for such Award (each, a "Restricted Stock Award").

     (b)  TERMS AND CONDITIONS. The Board shall determine the terms and
conditions of any such Restricted Stock Award, including the conditions for
repurchase (or forfeiture) and the issue price, if any. Any stock certificates
issued in respect of a Restricted Stock Award shall be registered in the name of
the Participant and, unless otherwise determined by the Board, deposited by the
Participant, together with a stock power endorsed in blank, with the Company (or
its designee). At the expiration of the applicable restriction periods, the
Company (or such designee) shall deliver the certificates no longer subject to
such restrictions to the Participant or if the Participant has died, to the
beneficiary designated, in a manner determined by the Board, by a Participant to
receive amounts due or exercise rights of the Participant in the event of the
Participant's death (the "Designated Beneficiary"). In the absence of an
effective designation by a Participant, Designated Beneficiary shall mean the
Participant's estate.

7.   OTHER STOCK-BASED AWARDS

The Board shall have the right to grant other Awards based upon the Common Stock
having such terms and conditions as the Board may determine, including the grant
of shares based upon certain conditions, the grant of securities convertible
into Common Stock and the grant of stock appreciation rights.

                                      -3-
<PAGE>   4

8.   ADJUSTMENTS FOR CHANGES IN COMMON STOCK AND CERTAIN OTHER EVENTS

     (a)  CHANGES IN CAPITALIZATION. In the event of any stock split, reverse
stock split, stock dividend, recapitalization, combination of shares,
reclassification of shares, spin-off or other similar change in capitalization
or event, or any distribution to holders of Common Stock other than a normal
cash dividend, (i) the number and class of securities available under this Plan,
(ii) the number and class of securities and exercise price per share subject to
each outstanding Option, (iii) the repurchase price per share subject to each
outstanding Restricted Stock Award and (iv) the terms of each other outstanding
Award shall be appropriately adjusted by the Company (or substituted Awards may
be made, if applicable) to the extent the Board shall determine, in good faith,
that such an adjustment (or substitution) is necessary and appropriate. If this
Section 8(a) applies and Section 8(c) also applies to any event, Section 8(c)
shall be applicable to such event, and this Section 8(a) shall not be
applicable.

     (b)  LIQUIDATION OR DISSOLUTION. In the event of a proposed liquidation or
dissolution of the Company, the Board shall upon written notice to the
Participants provide that all then unexercised Options will (i) become
exercisable in full as of a specified time at least 10 business days prior to
the effective date of such liquidation or dissolution and (ii) terminate
effective upon such liquidation or dissolution, except to the extent exercised
before such effective date. The Board may specify the effect of a liquidation or
dissolution on any Restricted Stock Award or other Award granted under the Plan
at the time of the grant of such Award.

     (c)  ACQUISITION EVENTS

          (1)  DEFINITION. An "Acquisition Event" shall mean: (a) any merger or
consolidation of the Company with or into another entity as a result of which
the Common Stock is converted into or exchanged for the right to receive cash,
securities or other property or (b) any exchange of shares of the Company for
cash, securities or other property pursuant to a statutory share exchange
transaction.

          (2)  CONSEQUENCES OF AN ACQUISITION EVENT ON OPTIONS. Upon the
occurrence of an Acquisition Event, or the execution by the Company of any
agreement with respect to an Acquisition Event, the Board shall provide that all
outstanding Options shall be assumed, or equivalent options shall be
substituted, by the acquiring or succeeding corporation (or an affiliate
thereof). For purposes hereof, an Option shall be considered to be assumed if,
following consummation of the Acquisition Event, the Option confers the right to
purchase, for each share of Common Stock subject to the Option immediately prior
to the consummation of the Acquisition Event, the consideration (whether cash,
securities or other property) received as a result of the Acquisition Event by
holders of Common Stock for each share of Common Stock held immediately prior to
the consummation of the Acquisition Event (and if holders were offered a choice
of consideration, the type of consideration chosen by the holders of a majority
of the outstanding shares of Common Stock); provided, however, that if the
consideration received as a result of the Acquisition Event is not solely common
stock of the acquiring or succeeding corporation (or an affiliate thereof), the
Company may, with the consent of the acquiring or succeeding corporation,
provide for the consideration to be received upon the exercise of Options to
consist solely of common stock of the acquiring or succeeding corporation (or an
affiliate thereof) equivalent in fair market value to the per share
consideration received by holders of outstanding shares of Common Stock as a
result of the Acquisition Event.

                                      -4-
<PAGE>   5

          Notwithstanding the foregoing, if the acquiring or succeeding
corporation (or an affiliate thereof) does not agree to assume, or substitute
for, such Options, then the Board shall, upon written notice to the
Participants, provide that all then unexercised Options will become exercisable
in full as of a specified time prior to the Acquisition Event and will terminate
immediately prior to the consummation of such Acquisition Event, except to the
extent exercised by the Participants before the consummation of such Acquisition
Event; provided, however, that in the event of an Acquisition Event under the
terms of which holders of Common Stock will receive upon consummation thereof a
cash payment for each share of Common Stock surrendered pursuant to such
Acquisition Event (the "Acquisition Price"), then the Board may instead provide
that all outstanding Options shall terminate upon consummation of such
Acquisition Event and that each Participant shall receive, in exchange therefor,
a cash payment equal to the amount (if any) by which (A) the Acquisition Price
multiplied by the number of shares of Common Stock subject to such outstanding
Options (whether or not then exercisable), exceeds (B) the aggregate exercise
price of such Options.

          (3)  CONSEQUENCES OF AN ACQUISITION EVENT ON RESTRICTED STOCK AWARDS.
Upon the occurrence of an Acquisition Event, the repurchase and other rights of
the Company under each outstanding Restricted Stock Award shall inure to the
benefit of the Company's successor and shall apply to the cash, securities or
other property which the Common Stock was converted into or exchanged for
pursuant to such Acquisition Event in the same manner and to the same extent as
they applied to the Common Stock subject to such Restricted Stock Award.

          (4)  CONSEQUENCES OF AN ACQUISITION EVENT ON OTHER AWARDS. The Board
shall specify the effect of an Acquisition Event on any other Award granted
under the Plan at the time of the grant of such Award.

9.   GENERAL PROVISIONS APPLICABLE TO AWARDS

     (a)  TRANSFERABILITY OF AWARDS. Except as the Board may otherwise determine
or provide in an Award, Awards shall not be sold, assigned, transferred, pledged
or otherwise encumbered by the person to whom they are granted, either
voluntarily or by operation of law, except by will or the laws of descent and
distribution, and, during the life of the Participant, shall be exercisable only
by the Participant. References to a Participant, to the extent relevant in the
context, shall include references to authorized transferees.

     (b)  DOCUMENTATION. Each Award shall be evidenced by a written instrument
in such form as the Board shall determine. Each Award may contain terms and
conditions in addition to those set forth in the Plan.

     (c)  BOARD DISCRETION. Except as otherwise provided by the Plan, each Award
may be made alone or in addition or in relation to any other Award. The terms of
each Award need not be identical, and the Board need not treat Participants
uniformly.

     (d)  TERMINATION OF STATUS. The Board shall determine the effect on an
Award of the disability, death, retirement, authorized leave of absence or other
change in the employment or other status of a Participant and the extent to
which, and the period during which, the Participant,

                                      -5-
<PAGE>   6

the Participant's legal representative, conservator, guardian or Designated
Beneficiary may exercise rights under the Award.

     (e)  WITHHOLDING. Each Participant shall pay to the Company, or make
provision satisfactory to the Board for payment of, any taxes required by law to
be withheld in connection with Awards to such Participant no later than the date
of the event creating the tax liability. Except as the Board may otherwise
provide in an Award, when the Common Stock is registered under the Exchange Act,
Participants may, to the extent then permitted under applicable law, satisfy
such tax obligations in whole or in part by delivery of shares of Common Stock,
including shares retained from the Award creating the tax obligation, valued at
their Fair Market Value. The Company may, to the extent permitted by law, deduct
any such tax obligations from any payment of any kind otherwise due to a
Participant.

     (f)  AMENDMENT OF AWARD. The Board may amend, modify or terminate any
outstanding Award, including but not limited to, substituting therefor another
Award of the same or a different type, changing the date of exercise or
realization, and converting an Incentive Stock Option to a Nonstatutory Stock
Option, provided that the Participant's consent to such action shall be required
unless the Board determines that the action, taking into account any related
action, would not materially and adversely affect the Participant.

     (g)  CONDITIONS ON DELIVERY OF STOCK. The Company will not be obligated to
deliver any shares of Common Stock pursuant to the Plan or to remove
restrictions from shares previously delivered under the Plan until (i) all
conditions of the Award have been met or removed to the satisfaction of the
Company, (ii) in the opinion of the Company's counsel, all other legal matters
in connection with the issuance and delivery of such shares have been satisfied,
including any applicable securities laws and any applicable stock exchange or
stock market rules and regulations and (iii) the Participant has executed and
delivered to the Company such representations or agreements as the Company may
consider appropriate to satisfy the requirements of any applicable laws, rules
or regulations.

     (h)  ACCELERATION. The Board may at any time provide that any Options shall
become immediately exercisable in full or in part, that any Restricted Stock
Awards shall be free of restrictions in full or in part or that any other Awards
may become exercisable in full or in part or free of some or all restrictions or
conditions, or otherwise realizable in full or in part, as the case may be.

10.  MISCELLANEOUS

     (a)  NO RIGHT TO EMPLOYMENT OR OTHER STATUS. No person shall have any claim
or right to be granted an Award, and the grant of an Award shall not be
construed as giving a Participant the right to continued employment or any other
relationship with the Company. The Company expressly reserves the right at any
time to dismiss or otherwise terminate its relationship with a Participant free
from any liability or claim under the Plan, except as expressly provided in the
applicable Award.

     (b)  NO RIGHTS AS STOCKHOLDER. Subject to the provisions of the applicable
Award, no Participant or Designated Beneficiary shall have any rights as a
stockholder with respect to any

                                      -6-
<PAGE>   7

shares of Common Stock to be distributed with respect to an Award until becoming
the record holder of such shares. Notwithstanding the foregoing, in the event
the Company effects a split of the Common Stock by means of a stock dividend and
the exercise price of and the number of shares subject to such Option are
adjusted as of the date of the distribution of the dividend (rather than as of
the record date for such dividend), then an optionee who exercises an Option
between the record date and the distribution date for such stock dividend shall
be entitled to receive, on the distribution date, the stock dividend with
respect to the shares of Common Stock acquired upon such Option exercise,
notwithstanding the fact that such shares were not outstanding as of the close
of business on the record date for such stock dividend.

     (c)  EFFECTIVE DATE AND TERM OF PLAN. The Plan shall become effective on
the date on which it is adopted by the Board. No Awards shall be granted under
the Plan after the completion of ten years from the earlier of (i) the date on
which the Plan was adopted by the Board or (ii) the date the Plan was approved
by the Company's stockholders, but Awards previously granted may extend beyond
that date.

     (d)  AMENDMENT OF PLAN. The Board may amend, suspend or terminate the Plan
or any portion thereof at any time.

     (e)  GOVERNING LAW. The provisions of the Plan and all Awards made
hereunder shall be governed by and interpreted in accordance with the laws of
the State of Delaware, without regard to any applicable conflicts of law.

Adopted and approved by the Board of Directors and the Sole Stockholder of the
Company on June 16, 1999.

Section 4 (Stock Available For Awards) was restated on July 30, 1999 to reflect
that Awards may be made under the Plan for up to 2,000,000 shares of Common
Stock, after giving effect to a 10-for-1 split of the Company's Common Stock on
July 30, 1999.

                                      -7-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00006-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00006-of-00352.parquet"}]]